ATOS

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

08/28 08:30 am

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

10/14 05:08 pm

Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

06/28 08:30 am

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

06/25 09:40 am

Atossa Set to Join Russell 3000® Index Effective June 28, 2024

06/17 08:30 am

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

06/06 09:40 am

Atossa to Present at the Sidoti Small-Cap Investor Conference

06/05 08:30 am

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

05/28 08:30 am

Atossa Genetics Inc. (ATOS) is a Great Momentum Stock: Should You Buy?

05/20 12:00 pm

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

05/15 08:30 am

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

05/13 08:50 am

Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines

05/07 08:30 am

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen

04/29 08:30 am

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

04/11 10:10 am

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

04/11 08:30 am

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

04/09 11:59 am

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

04/01 04:00 pm

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

03/19 08:30 am

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

03/18 08:30 am

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors

03/12 08:30 am

Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?

12/08 10:40 am

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

11/20 09:30 am

Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

11/13 10:00 am

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

11/09 10:00 am

Atossa to Present at Cantor Fitzgerald Global Healthcare Conference 2023

09/18 08:30 am

Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst

09/08 02:47 pm

Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023

09/08 11:00 am

Atossa Therapeutics Receives Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada

07/20 09:15 am

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

07/13 04:15 pm

Atossa Therapeutics Provides Enrollment Update for Ongoing Phase 2 Karisma-Endoxifen Clinical Trial

07/10 09:15 am

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

07/06 09:15 am

Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial

06/28 09:15 am

Atossa Therapeutics Announces $10M Stock Repurchase Program

06/27 09:15 am

Atossa Therapeutics Announces Sponsorship of Are You Dense MusicFest 2023

06/22 04:15 pm

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

06/21 10:13 am

Atossa to Participate in Fireside Chat at Healthcare Virtual Conference Presented by Maxim Group LLC

06/14 09:15 am

Atossa Completes Enrollment of Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer

06/12 09:15 am

Atossa Appoints Life Sciences Financial and Operations Industry Veteran Greg Weaver as Chief Financial Officer

06/01 09:10 am

Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update

05/15 09:10 am

Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

05/09 09:15 am

Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment”

04/27 09:15 am

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

03/22 04:05 pm

Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial

03/21 09:15 am

Atossa to Present at the Sidoti Small-Cap Virtual Conference

03/15 09:25 am

Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer

02/23 10:15 am

Best Penny Stocks To Buy? 4 Stocks Under $3 To Watch This Week

02/13 03:47 pm

Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen

02/13 10:15 am

Atossa Therapeutics Issues Letter to Shareholders

01/25 10:15 am

Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations

12/07 09:00 am

Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy

11/01 09:15 am